Munich, Germany and San Francisco, USA, June 09, 2026 – CatalYm today announced the appointment of Peter Garcia as Chief Financial Officer (CFO). Mr. Garcia brings more than three decades of biotechnology and oncology financial leadership experience, with a proven track record of leading transformative financings, strategic transactions, and scaling finance organizations to support global clinical development and commercialization.

Schlieren / Zurich, Switzerland, 5 June, 2026 – Memo Therapeutics AG  ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today shared additional data analysis from its Phase II study of potravitug at the European Renal Association (ERA) Congress.

Munich, Germany and San Francisco, USA, April 29, 2026 – CatalYm today announced the appointment of seasoned biotech executive Christian S. Schade as Chairman of the Board of Directors. With over 30 years of executive leadership experience across private and public biopharma companies, Mr. Schade will provide board leadership at a crucial stage for the company, following the initiation of four late-stage clinical studies of its lead candidate, the GDF-15 inhibitor visugromab.

Munich, Germany and San Francisco, USA, April 23, 2026 – CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia International Trial, NCT07112196). The global study is evaluating the company's lead anti-GDF-15 antibody visugromab in patients with cancer-associated cachexia.

Munich, Germany and San Francisco, USA, April 7, 2026 – CatalYm today announced that the first patient has been dosed in the GDFATHER-HCC-01 trial (NCT07219459). The trial evaluates the company's lead anti-GDF-15 antibody visugromab in combination with chemoimmunotherapy as a second-line (2L) treatment for patients with unresectable or metastatic hepatocellular carcinoma (HCC).

Schlieren / Zurich, Switzerland, 9 February, 2026 – Memo Therapeutics AG  ("MTx") today announced it has entered into a strategic collaboration and exclusive option-to-license agreement with CSL, a global leader in developing and delivering high-quality medicines that treat people with rare and serious diseases, for MTx's recombinant polyclonal IgG technology.

NEW YORK, January, 28th, 2026 – Sword Health, the world's leading AI Health company, today announced the acquisition of Kaia Health, a digital health company focused on musculoskeletal (MSK) and pulmonary care, in a deal valued at $285 million. The acquisition reinforces Sword's position as the fastest-growing AI Care platform in the world, expanding its ability to deliver high-quality, scalable care to new populations in the US while entering the German market.

Schlieren / Zurich, Switzerland, 9 January, 2026 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique human immune responses into superior medicines to treat viral infections and cancer, today announces the publication of a qualitative research paper titled 'Development of a Conceptual Model of BKV Impacts on Health-Related Quality of Life in Kidney Transplant Recipients' in the Journal of Patient-Reported Outcomes.

Schlieren / Zurich, Switzerland, 18 December, 2025 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that the European Commission has granted orphan designation in the European Union (EU) for potravitug, a highly potent human BK polyomavirus ("BKPyV")-neutralizing antibody for the treatment of BKPyV infection in kidney transplant recipients.

Schlieren / Zurich, Switzerland, 7 November, 2025 – Memo Therapeutics AG ("MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces that it has presented long term follow-up data from its Phase II SAFE KIDNEY trial of therapeutic antibody potravitug for the treatment of BK polyomavirus (BKPyV) infection in kidney transplant recipients (KTRs) at the American Society of Nephrology (ASN) Kidney Week Meeting from November 5–9, 2025, in Houston, Texas.